Latest Articles

Publication Date
BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial - BioSpace

BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial BioSpace

Published: April 13, 2026, 5:57 p.m.
Social Media Health Information Formats and Endometriosis Treatment-Seeking Intentions: A Randomized Controlled Trial.

BackgroundDespite many women learning about endometriosis on social media, posts about the condition often fail to reflect current evidence. With the content and credibility of online health messages being found …

Published: April 13, 2026, midnight
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive

Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer OncLive

Published: April 12, 2026, 9:01 p.m.
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer - OncLive

Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer OncLive

Published: April 12, 2026, 6:25 p.m.
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive

Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer OncLive

Published: April 12, 2026, 2:35 p.m.
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times

Published: April 11, 2026, 11:01 a.m.
New perspectives in managing chronic pelvic pain in Endometriosis: the role of GnRH antagonists versus dienogest.

Endometriosis is a chronic, estrogen-dependent inflammatory disease affecting about 10% of reproductive-age women. Chronic pelvic pain is its most disabling symptom, and available therapies often show limited long-term efficacy and …

Published: April 9, 2026, midnight
Linzagolix, with and without add-back therapy, in women with endometriosis-associated pain: results from EDELWEISS 6, a double-blind randomized extension and withdrawal study.

Was the efficacy of linzagolix, observed at 6 months in women with endometriosis-associated pain, maintained when administered for an additional 6 months?

Published: April 8, 2026, midnight
Clinical Efficacy of Dienogest for Symptomatic Adenomyosis.

Background: This study was conducted to assess whether medical treatment with dienogest (DNG) is effective in women with symptomatic adenomyosis. Methods: This single-center, retrospective study included patients with symptomatic adenomyosis …

Published: April 6, 2026, midnight
Contemporary Diagnostic and Therapeutic Approaches in Endometriosis: A Systematic Review.

Endometriosis is a chronic inflammatory disorder characterized by pelvic pain, infertility, and reduced quality of life, and is frequently associated with prolonged diagnostic delay and variable treatment response. Although advances …

Published: April 3, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!